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Abstract: We report the case of a young girl who presented with
hemiparesis, seizures, and subtle features consistent with a linear form of
facial morphea (en coup de sabre). She was treated with pulsed parenteral
steroids and oral steroids and started on methotrexate. Magnetic
resonance imaging results and neurologic problems improved after
6 months. Switching off inflammation early in the course of disease
seemed to reverse some of the central nervous system changes.
Assessment of children with unexplained hemiparesis and seizures
should include careful examination of the face and scalp, looking for
subtle signs of skin change and asymmetry. This is one of the few
reported cases of neuroradiologic improvement after immunosuppressive
treatment in a child with en coup de sabre.
Scleroderma is a nonhereditary connective tissue
disorder that can broadly be divided into systemic
disease (with internal organ involvement) and local-
ized disease (limited to the skin). Localized sclero-
derma (morphea) is further subdivided into linear,
generalized, pansclerotic, and mixed types (1). Pro-
gression to systemic scleroderma in children is exceed-
ingly rare (2).
CASE REPORT
A previously healthy girl born to a consanguineous
couple from Pakistan, presented at the age of 10 years
with acute onset of right-sided weakness, motor
dyspraxia, and right facial weakness.
She had no Raynaud’s phenomenon, arthritis, dys-
phagia, sicca symptoms, or weight loss. There was no
historyofdrug exposure, chemicals, tickbite, or trauma.
Echocardiography to exclude infective endocarditis or
intracardiac thrombuswasnormal.Cerebral spinal ﬂuid
(CSF) protein, lactate, cell count and culture, and
oligoclonal bandswerenormal.CSFvirology, including
parechovirus, cytomegalovirus, Epstein–Barr virus,
enterovirus, herpes simplex virus, human herpes virus
6, and varicella zoster virus according to polymerase
chain reaction were unremarkable.
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Further investigations included complete blood
count, urea, creatinine, electrolytes, liver function test,
thyroid function test (free thyroxine 16.0 pmol/L
[range 10.8–19.0 pmol/L], thyroid-stimulating hor-
mone 1.1 mU/L [normal <6.0 mU/L]), serum angio-
tensin-converting enzyme (30 U/L [range 0–90 U/L]),
serum amyloid protein, glucose (3.7 mmol/L [range
3.5–5.5 mmol/L]), lactate (1.0 mmol/L [range 0.7–
2.1 mmol/L]), folate (6.3 lg/L [range 1.0–10.2 lg/L]),
erythrocyte sedimentation rate, and clotting screen
were all within normal reference ranges.
Her immunoglobulin (Ig) levels, including IgG
(10.4 g/L [range 5.4–16.1 g/L]), IgA (range 1.17 g/L
[range 0.7–2.5 g/L]), and IgM (1.05 g/L [range 0.5–
1.8 g/L]), were also within normal limits.
Screening for connective tissue and other auto-
antibody diseases, including antinuclear antibodies
(ANAs), anti-double-strand DNA (1.0 IU/mL [range
0–9.9 IU/mL]), tissue transglutaminase antibodies
(0.20 U/mL [range 0.0–6.9 U/mL]), PR3 (0.30 IU/mL
[range 0–1.99 IU/mL]), myeloperoxidase (<0.20 IU/
mL [range 0–3.49 IU/mL]), rheumatoid factor
(<20.0 IU/mL [range 0–20 IU/mL]), and thyroid
peroxidase antibody (<33.4 IU/mL [normal <60 IU/
mL]) were all normal as well. Initial computed
tomography (CT) (Fig. 1) and magnetic resonance
imaging (MRI) (Fig. 2) of the brain showed lep-
tomeningeal, gyral, and basal ganglia calciﬁcation
with adjacent white matter signal abnormalities in the
left hemisphere, along with generalized swelling of the
Figure 1. Axial computed tomography scans through the frontal and parietal lobes show leptomeningeal and gyral
calcification in the brain underlying the ipsilateral region of thinning of the scalp.
Figure 2. Axial T2-weighted images show patchy white matter abnormality in the left inferior parietal lobe and foci of
calcification in the left basal ganglia and adjacent capsular white matter. Subtle generalized swelling of the left hemisphere
is also demonstrated.
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left cerebral hemisphere. Intracranial angiography
was normal. Electroencephalography demonstrated
nonspeciﬁc dysfunction over the left posterior quad-
rant. She was started on phenytoin because of
continued ictal features and the self-resolved episode
of right-sided weakness.
Shortly before discharge after ﬁrst presentation,
she was noted to have a depressed hypopigmented
band of skin extending from the left brow into the
scalp (Figs. 3 and 4). Skin biopsy was examined at
several levels, with underlying fatty tissue and skeletal
muscle. The overlying epidermis showed mild atrophy
and a lack of rete ridges. There were occasional
intraepithelial lymphocytes, but there was no obvious
hydropic degeneration of the basal keratinocytes.
There were pigment-laden macrophages in the super-
ﬁcial dermis, and the reticular dermis was noted to be
thick, with an excess of coarse collagen bundles. There
was a mild mononuclear, predominantly lymphocytic,
inﬂammatory cell inﬁltrate between the collagen
bundles and around the vessels and the skin appen-
dages. There was no signiﬁcant ﬁbrosis in the subcu-
taneous tissue and no fat entrapping. The changes
were consistent with morphea, supporting a diagnosis
of en coup de sabre (ECDS) morphea.
She was treated with pulsed methylprednisolone
followed by oral steroids and methotrexate (15 mg/m2
once a week). Our pulse protocol consists of three
doses over three consecutive days, usually repeated on
the same days a week later. Each pulse consists of
30 mg/kg of methylprednisolone (maximum 1,000 mg).
She had three self-limited 24-hour episodes of right-
sided hemiparesis and aphasia over the next 6 months
while taking aspirin, oral prednisolone, phenytoin,
and methotrexate. Her neurologic episodes declined
in frequency and severity over the next 10 months.
She was switched to levetiracetam, which helped but
did not completely resolve her seizures. Follow-up
MRI after 6 months showed partial resolution of the
white matter abnormality (Fig. 5).
DISCUSSION
Linear scleroderma is a connective tissue disorder of
unknown etiology that may relapse and remit and
cause functional impairment and disﬁgurement. Two-
thirds of patients with linear morphea are younger
than 18 years (2). The main concern in children is the
risk of long-term complications due to musculoskele-
tal eﬀects of the disease process, which include limb
and facial asymmetry. Psychological problems can
result from pronounced disﬁgurement. Neurologic
abnormalities have been reported with ECDS on
Figure 3. Scalp shows scarring alopecia.
Figure 4. Left frontal region shows marked thinning and
sclerotic changes.
Figure 5. Axial T2-weighted image performed 6 months
later shows partial resolution of the parietal white matter
abnormality. The calcific foci are unchanged. The
hemispheric swelling has resolved.
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initial presentation (2). In all of the subclasses of
linear scleroderma, the ECDS and Parry–Romberg
subtypes are the only ones associated with severe
neurologic abnormalities (2).
Her neuroradiologic examinations revealed white
matter lesions and intracranial calciﬁcation, which are
already reported in the medical literature (3). Her
calcium deposits were thought to be due to an early
primary cerebral inﬂammatory process, because these
have been previously described in the brain in linear
scleroderma (4). Epileptic seizures are a known major
neurologic complication of ECDS and progressive
facial hemiatrophy (3), such as observed in our
patient.
Common neuroimaging ﬁndings of this syndrome
are calciﬁcation on CT and high-intensity areas on
MRI (5). The localized white matter signal abnor-
mality could have been due to cerebral edema
secondary to seizure activity as well, but serial MRIs
(three in total) refuted this correlation, because no
epileptiform activity was recorded on repeated pro-
longed electroencephalographic monitoring. This
placed an inﬂammatory process at the top of the
diﬀerential diagnosis. Her repeated neurologic exam-
inations were unremarkable, but MRI had persistent
changes that coincided well clinically with her diﬃ-
cult-to-treat epilepsy. She continued on oral aspirin
and antiepileptic treatment to cover the possibility of
thrombotic or epileptic episodes.
Several theories about the pathogenesis of linear
morphea have been suggested, including chronic
inﬂammation, abnormal perfusion, cortical dysgene-
sis, autoimmune disease, and sympathetic overexcita-
tion (3). This case points to an inﬂammatory and
potentially reversible process. It is possible that con-
ﬂicting ﬁndings might represent the disease process at
diﬀerent points in its evolution. Facial linear morphea
aﬀects the central nervous system in nearly two-thirds
of patients, as previously reported (6).
The previous reports of onset in the ﬁrst or second
decade, female predilection, and commonly aﬀecting
the left side of face (7) ﬁt well with our patient’s
demographic characteristics.
Because of its uncommon occurrence, a spectrum
of agents has historically been used to treat it,
including agents such as D-penicillamine, oral ster-
oids, antimalarial medications, methotrexate with
pulse oral steroids, topical calcipotriol, and psoralen
with ultraviolet A light (8).
We think that switching oﬀ the inﬂammatory
process early by using corticosteroids and disease-
modifying antirheumatic agents not only helped
reduce inﬂammation, but also reversed the initial
damage caused by underlying inﬂammatory pro-
cesses.
Her ictal features declined after treatment, corre-
lating well with her neuroradiologic follow-up images.
We did not see any signiﬁcant electroencephalo-
graphic abnormalities, although she was extensively
screened, and electroencephalographic changes have
remained nonspeciﬁc.
CONCLUSION
This case highlights the underrecognized relationship
between neurologic complications and linear sclero-
derma. Neurologic manifestations were the presenting
symptom, before the diagnosis of ECDS, which is
unusual. Although our patient still has signiﬁcant
neurologic symptoms despite radiologic improvement
on antiinﬂammatory treatment, this might be sec-
ondary to her residual intracerebral calciﬁcations,
because these have not responded to treatment and
can still be seen on imaging. This calciﬁcation may
represent older, more refractory changes. We would
suggest a baseline MRI in patients with a new
diagnosis of ECDS as well as in all patients with
ECDS who develop any neurologic symptoms. This is
one of the few reported cases of neuroradiologic
improvement in a child with ECDS after treatment.
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